Oruka Therapeutics (NASDAQ:ORKA) Earns Buy Rating from Analysts at UBS Group

UBS Group started coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a report issued on Wednesday morning, Marketbeat reports. The firm issued a buy rating and a $50.00 target price on the stock.

A number of other research firms have also recently issued reports on ORKA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 8th. Barclays started coverage on Oruka Therapeutics in a research note on Monday, October 13th. They issued an “overweight” rating and a $48.00 price target on the stock. Guggenheim started coverage on shares of Oruka Therapeutics in a research report on Monday, October 27th. They set a “buy” rating and a $60.00 price objective for the company. BTIG Research upped their price objective on shares of Oruka Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Finally, Piper Sandler began coverage on shares of Oruka Therapeutics in a research report on Thursday, December 18th. They issued an “overweight” rating and a $75.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.00.

Oruka Therapeutics Price Performance

Oruka Therapeutics stock opened at $27.86 on Wednesday. The company’s 50-day moving average is $29.14 and its 200-day moving average is $21.33. The firm has a market capitalization of $1.35 billion, a PE ratio of -14.66 and a beta of -0.39. Oruka Therapeutics has a fifty-two week low of $5.49 and a fifty-two week high of $32.64.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Wednesday, November 12th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.01. As a group, analysts expect that Oruka Therapeutics will post -3.41 EPS for the current year.

Insider Buying and Selling at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction on Friday, December 19th. The stock was sold at an average price of $30.61, for a total transaction of $214,270.00. Following the completion of the sale, the insider owned 1,518 shares of the company’s stock, valued at approximately $46,465.98. This trade represents a 82.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 24.69% of the company’s stock.

Hedge Funds Weigh In On Oruka Therapeutics

Hedge funds have recently bought and sold shares of the business. Rhumbline Advisers boosted its stake in shares of Oruka Therapeutics by 6.1% in the third quarter. Rhumbline Advisers now owns 30,327 shares of the company’s stock valued at $583,000 after buying an additional 1,757 shares during the period. PNC Financial Services Group Inc. bought a new position in Oruka Therapeutics during the 3rd quarter worth $39,000. Russell Investments Group Ltd. acquired a new position in Oruka Therapeutics in the 3rd quarter valued at $43,000. BNP Paribas Financial Markets raised its holdings in Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after acquiring an additional 2,306 shares in the last quarter. Finally, Legal & General Group Plc bought a new stake in shares of Oruka Therapeutics during the 2nd quarter valued at $28,000. 56.44% of the stock is owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.